{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:37:27Z","timestamp":1791466647077,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40290-020-00343-y","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T09:03:53Z","timestamp":1595495033000},"page":"233-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The NIMH \u2018Fast-Fail Trials\u2019 (FAST) Initiative: Rationale, Promise, and Progress"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5710-1289","authenticated-orcid":false,"given":"Margaret C.","family":"Grabb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9114-7803","authenticated-orcid":false,"given":"Mi","family":"Hillefors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Z.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"issue":"3","key":"343_CR1","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.neuron.2014.10.027","volume":"84","author":"DW Choi","year":"2014","unstructured":"Choi DW, Armitage R, Brady LS, Coetzee T, Fisher W, Hyman S, et al. Medicines for the mind: policy-based \u201cpull\u201d incentives for creating breakthrough CNS drugs. Neuron. 2014;84(3):554\u201363. https:\/\/doi.org\/10.1016\/j.neuron.2014.10.027.","journal-title":"Neuron"},{"issue":"7","key":"343_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1176\/appi.ajp.2010.09091379","volume":"167","author":"TR Insel","year":"2010","unstructured":"Insel TR, Cuthbert BN, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):750\u20131.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"343_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/da.22500","volume":"33","author":"WA Carlezon Jr","year":"2016","unstructured":"Carlezon WA Jr, Krystal AD. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress Anxiety. 2016;33(10):895\u2013906. https:\/\/doi.org\/10.1002\/da.22500.","journal-title":"Depress Anxiety"},{"issue":"1","key":"343_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1124\/jpet.105.092304","volume":"316","author":"WA Carlezon","year":"2006","unstructured":"Carlezon WA, B\u00e9guin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, et al. Depressive-like effects of the \u03ba-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther. 2006;316(1):440\u20137. https:\/\/doi.org\/10.1124\/jpet.105.092304.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"343_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.brainresrev.2009.09.008","volume":"62","author":"AW Bruijnzeel","year":"2009","unstructured":"Bruijnzeel AW. kappa-Opioid receptor signaling and brain reward function. Brain Res Rev. 2009;62(1):127\u201346. https:\/\/doi.org\/10.1016\/j.brainresrev.2009.09.008.","journal-title":"Brain Res Rev"},{"issue":"1","key":"343_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neuropharm.2011.06.014","volume":"62","author":"E Chartoff","year":"2012","unstructured":"Chartoff E, Sawyer A, Rachlin A, Potter D, Pliakas A, Carlezon WA. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology. 2012;62(1):167\u201376. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.06.014.","journal-title":"Neuropharmacology"},{"issue":"2","key":"343_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00213-010-1836-5","volume":"210","author":"SR Ebner","year":"2010","unstructured":"Ebner SR, Roitman MF, Potter DN, Rachlin AB, Chartoff EH. Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology. 2010;210(2):241\u201352. https:\/\/doi.org\/10.1007\/s00213-010-1836-5.","journal-title":"Psychopharmacology"},{"issue":"1","key":"343_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0304-3940(94)90559-2","volume":"181","author":"IM Maisonneuve","year":"1994","unstructured":"Maisonneuve IM, Archer S, Glick SD. U50,488, a \u03ba opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett. 1994;181(1):57\u201360. https:\/\/doi.org\/10.1016\/0304-3940(94)90559-2.","journal-title":"Neurosci Lett"},{"issue":"8","key":"343_CR9","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1523\/JNEUROSCI.5973-10.2011","volume":"31","author":"JW Muschamp","year":"2011","unstructured":"Muschamp JW, Van't Veer A, Parsegian A, Gallo MS, Chen M, Neve RL, et al. Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats. J Neurosci. 2011;31(8):3095\u2013103. https:\/\/doi.org\/10.1523\/JNEUROSCI.5973-10.2011.","journal-title":"J Neurosci"},{"issue":"11","key":"343_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.biopsych.2008.05.029","volume":"64","author":"HC Tomasiewicz","year":"2008","unstructured":"Tomasiewicz HC, Todtenkopf MS, Chartoff EH, Cohen BM, Carlezon WA Jr. The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry. 2008;64(11):982\u20138. https:\/\/doi.org\/10.1016\/j.biopsych.2008.05.029.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"343_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","volume":"210","author":"S Wee","year":"2010","unstructured":"Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology. 2010;210(2):121\u201335. https:\/\/doi.org\/10.1007\/s00213-010-1825-8.","journal-title":"Psychopharmacology"},{"key":"343_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nrd.2018.222","volume":"18","author":"AD Krystal","year":"2018","unstructured":"Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, et al. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2018;18:82\u20134. https:\/\/doi.org\/10.1038\/nrd.2018.222.","journal-title":"Nat Rev Drug Discov"},{"key":"343_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","volume":"77","author":"LM Rorick-Kehn","year":"2014","unstructured":"Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014;77:131\u201344. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.09.021.","journal-title":"Neuropharmacology"},{"issue":"9","key":"343_CR14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/jcph.286","volume":"54","author":"SL Lowe","year":"2014","unstructured":"Lowe SL, Wong CJ, Witcher J, Gonzales CR, Dickinson GL, Bell RL, et al. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol. 2014;54(9):968\u201378. https:\/\/doi.org\/10.1002\/jcph.286.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"343_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2967\/jnumed.112.109512","volume":"54","author":"M-Q Zheng","year":"2013","unstructured":"Zheng M-Q, Nabulsi N, Kim SJ, Tomasi G, Lin S-F, Mitch C, et al. Synthesis and evaluation of 11C-LY2795050 as a \u03ba-opioid receptor antagonist radiotracer for PET imaging. J Nucl Med. 2013;54(3):455\u201363. https:\/\/doi.org\/10.2967\/jnumed.112.109512.","journal-title":"J Nucl Med"},{"issue":"7","key":"343_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.biopsych.2007.07.023","volume":"63","author":"B Knutson","year":"2008","unstructured":"Knutson B, Bhanji JP, Cooney RE, Atlas LY, Gotlib IH. Neural responses to monetary incentives in major depression. Biol Psychiatry. 2008;63(7):686\u201392. https:\/\/doi.org\/10.1016\/j.biopsych.2007.07.023.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"343_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1192\/bjp.167.1.99","volume":"167","author":"RP Snaith","year":"1995","unstructured":"Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99\u2013103. https:\/\/doi.org\/10.1192\/bjp.167.1.99.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"343_CR18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","volume":"26","author":"AD Krystal","year":"2020","unstructured":"Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, et al. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating kappa-opioid antagonism as a treatment for anhedonia. Nat Med. 2020;26(5):760\u20138. https:\/\/doi.org\/10.1038\/s41591-020-0806-7.","journal-title":"Nat Med"},{"issue":"10","key":"343_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301\u20138. https:\/\/doi.org\/10.1176\/ajp.148.10.1301.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"343_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199\u201321414. https:\/\/doi.org\/10.1001\/archpsyc.1994.03950030035004.","journal-title":"Arch Gen Psychiatry"},{"issue":"5381","key":"343_CR21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","volume":"281","author":"B Moghaddam","year":"1998","unstructured":"Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281(5381):1349\u201352. https:\/\/doi.org\/10.1126\/science.281.5381.1349.","journal-title":"Science"},{"issue":"9","key":"343_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nm1632","volume":"13","author":"ST Patil","year":"2007","unstructured":"Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med. 2007;13(9):1102\u20137. https:\/\/doi.org\/10.1038\/nm1632.","journal-title":"Nat Med"},{"key":"343_CR23","doi-asserted-by":"publisher","first-page":"758212","DOI":"10.1155\/2014\/758212","volume":"2014","author":"DH Adams","year":"2014","unstructured":"Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez JC. Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treatment. 2014;2014:758212. https:\/\/doi.org\/10.1155\/2014\/758212.","journal-title":"Schizophr Res Treatment"},{"issue":"3","key":"343_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","volume":"31","author":"BJ Kinon","year":"2011","unstructured":"Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31(3):349\u201355. https:\/\/doi.org\/10.1097\/JCP.0b013e318218dcd5.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"343_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","volume":"78","author":"BJ Kinon","year":"2015","unstructured":"Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015;78(11):754\u201362. https:\/\/doi.org\/10.1016\/j.biopsych.2015.03.016.","journal-title":"Biol Psychiatry"},{"key":"343_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuroimage.2012.09.037","volume":"64","author":"S De Simoni","year":"2013","unstructured":"De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C, et al. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage. 2013;64:75\u201390. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.09.037.","journal-title":"Neuroimage"},{"issue":"7","key":"343_CR27","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00213-018-4877-9","volume":"235","author":"MA Mehta","year":"2018","unstructured":"Mehta MA, Schmechtig A, Kotoula V, McColm J, Jackson K, Brittain C, et al. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects. Psychopharmacology. 2018;235(7):1875\u201386. https:\/\/doi.org\/10.1007\/s00213-018-4877-9.","journal-title":"Psychopharmacology"},{"issue":"1","key":"343_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamapsychiatry.2017.3572","volume":"75","author":"DC Javitt","year":"2018","unstructured":"Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. JAMA Psychiatry. 2018;75(1):11\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3572.","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"343_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1001\/jamapsychiatry.2015.0276","volume":"72","author":"JD Ragland","year":"2015","unstructured":"Ragland JD, Ranganath C, Harms MP, Barch DM, Gold JM, Layher E, et al. Functional and neuroanatomic specificity of episodic memory dysfunction in schizophrenia: a functional magnetic resonance imaging study of the relational and item-specific encoding task. JAMA Psychiatry. 2015;72(9):909\u201316. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0276.","journal-title":"JAMA Psychiatry"},{"key":"343_CR30","doi-asserted-by":"crossref","unstructured":"Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, et al. Clinical efficacy and target engagement of glutamatergic drugs: placebocControlled RCTs of pomaglumetad and TS-134 for reversal of ketamine-induced psychotic symptoms and PharmacoBOLD in healthy volunteers. medRxiv. 2020:2020.03.09.20029827. 10.1101\/2020.03.09.20029827.","DOI":"10.1101\/2020.03.09.20029827"},{"issue":"5","key":"343_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/JCP.0000000000000536","volume":"36","author":"MC Grabb","year":"2016","unstructured":"Grabb MC, Cross AJ, Potter WZ, McCracken JT. Derisking psychiatric drug development: the NIMH's fast fail program, a novel precompetitive model. J Clin Psychopharmacol. 2016;36(5):419\u201321. https:\/\/doi.org\/10.1097\/JCP.0000000000000536.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"343_CR32","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/ar.21252","volume":"294","author":"GJ Blatt","year":"2011","unstructured":"Blatt GJ, Fatemi SH. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat Rec (Hoboken). 2011;294(10):1646\u201352. https:\/\/doi.org\/10.1002\/ar.21252.","journal-title":"Anat Rec (Hoboken)"},{"key":"343_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroimage.2013.05.068","volume":"86","author":"W Gaetz","year":"2014","unstructured":"Gaetz W, Bloy L, Wang DJ, Port RG, Blaskey L, Levy SE, et al. GABA estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. Neuroimage. 2014;86:1\u20139. https:\/\/doi.org\/10.1016\/j.neuroimage.2013.05.068.","journal-title":"Neuroimage"},{"key":"343_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pscychresns.2016.09.007","volume":"256","author":"GS Drenthen","year":"2016","unstructured":"Drenthen GS, Barendse EM, Aldenkamp AP, van Veenendaal TM, Puts NA, Edden RA, et al. Altered neurotransmitter metabolism in adolescents with high-functioning autism. Psychiatry Res Neuroimaging. 2016;256:44\u20139. https:\/\/doi.org\/10.1016\/j.pscychresns.2016.09.007.","journal-title":"Psychiatry Res Neuroimaging"},{"issue":"1","key":"343_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1152\/jn.00539.2013","volume":"113","author":"EP Christian","year":"2015","unstructured":"Christian EP, Snyder DH, Song W, Gurley DA, Smolka J, Maier DL, et al. EEG-beta\/gamma spectral power elevation in rat: a translatable biomarker elicited by GABA(Aalpha2\/3)-positive allosteric modulators at nonsedating anxiolytic doses. J Neurophysiol. 2015;113(1):116\u201331. https:\/\/doi.org\/10.1152\/jn.00539.2013.","journal-title":"J Neurophysiol"},{"issue":"4","key":"343_CR36","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bph.14119","volume":"175","author":"SA Nickolls","year":"2018","unstructured":"Nickolls SA, Gurrell R, van Amerongen G, Kammonen J, Cao L, Brown AR, et al. Pharmacology in translation: the preclinical and early clinical profile of the novel alpha2\/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865. Br J Pharmacol. 2018;175(4):708\u201325. https:\/\/doi.org\/10.1111\/bph.14119.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"343_CR37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41401-018-0185-5","volume":"40","author":"X Chen","year":"2019","unstructured":"Chen X, van Gerven J, Cohen A, Jacobs G. Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety. Acta Pharmacol Sin. 2019;40(5):571\u201382. https:\/\/doi.org\/10.1038\/s41401-018-0185-5.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"343_CR38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00213-016-4506-4","volume":"234","author":"A Jucaite","year":"2017","unstructured":"Jucaite A, Cselenyi Z, Lappalainen J, McCarthy DJ, Lee CM, Nyberg S, et al. GABAA receptor occupancy by subtype selective GABAAalpha2,3 modulators: PET studies in humans. Psychopharmacology. 2017;234(4):707\u201316. https:\/\/doi.org\/10.1007\/s00213-016-4506-4.","journal-title":"Psychopharmacology"},{"issue":"6","key":"343_CR39","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/bcp.12413","volume":"78","author":"X Chen","year":"2014","unstructured":"Chen X, Jacobs G, de Kam M, Jaeger J, Lappalainen J, Maruff P, et al. The central nervous system effects of the partial GABA-A\u03b12,3-selective receptor modulator AZD7325 in comparison with lorazepam in healthy males. Br J Clin Pharmacol. 2014;78(6):1298\u2013314. https:\/\/doi.org\/10.1111\/bcp.12413.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"343_CR40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1162\/jocn.1996.8.6.551","volume":"8","author":"S Bentin","year":"1996","unstructured":"Bentin S, Allison T, Puce A, Perez E, McCarthy G. Electrophysiological studies of face perception in humans. J Cogn Neurosci. 1996;8(6):551\u201365. https:\/\/doi.org\/10.1162\/jocn.1996.8.6.551.","journal-title":"J Cogn Neurosci"},{"key":"343_CR41","volume-title":"Autism diagnostic observation schedule (ADOS-2). Modules 1 through 4","author":"CR Lord","year":"2012","unstructured":"Lord CR, Dilavore M, Risi PC, Gotham S, Bishop K, Somer L. Autism diagnostic observation schedule (ADOS-2). Modules 1 through 4. 2nd ed. Torrence, California: Western Psychological Services; 2012.","edition":"2"},{"issue":"10","key":"343_CR42","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1016\/j.jaac.2018.07.683","volume":"57","author":"JT McCracken","year":"2018","unstructured":"McCracken JT. 12.3 Target engagement of AZD7325 in adults with ASD. J Am Acad Child Adolesc Psychiatry. 2018;57(10):S287. https:\/\/doi.org\/10.1016\/j.jaac.2018.07.683.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"343_CR43","unstructured":"Fortress Biotech announces exclusive worldwide license agreement with AstraZeneca and Cincinnati Children\u2019s Hospital Medical Center to develop a novel treatment for select CNS disorders. Baergic Bio, a Fortress partner company, enters into an agreement with AstraZeneca for AZD7325, a novel \u03b12\/3-subtype-selective GABA A positive allosteric modulator. Globe Newswire; 2019."}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-020-00343-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-020-00343-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-020-00343-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T23:10:16Z","timestamp":1626995416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-020-00343-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1007\/s40290-020-00343-y","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"23 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist with the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Margaret C. Grabb and Mi Hillefors have no conflicts of interest that are directly relevant to the content of this article. William Z. Potter consulted for Otsuka, AgeneBio, Takeda, Lilly, Noven, and Karuna.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}